Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab plus EP chemotherapy with SBRT for first-line extensive-stage small-cell lung cancer
ChiCTR2000033558Phase 2Not yet recruiting
- Sponsor
- Cancer Diagnosis and Treatment Center of the Sixth Medical Center of PLA General Hospital
- Start
- Jul 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, etoposide, cisplatin and carboplatin in small cell lung cancer (SCLC), sponsored by Cancer Diagnosis and Treatment Center of the Sixth Medical Center of PLA General Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
durvalumabetoposidecisplatincarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2000033558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033558.